Hypoglycaemia risk with dual use of DPP-4 inhibitors and sulphonylureas

Sulphonylureas and hypoglycaemia.

DPP-4 Inhibitors

The first dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin was approved in 2006 as treatment for diabetes concurrently with lifestyle changes. A combined product of sitagliptin and glucophage was approved by the U.S. Food and Drug Administration in 2007. The second DPP-4 inhibitor, saxagliptin, was approved in theU.S. It was approved both as monotherapy as well as in combination with metform...

Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.

AIMS Indirect evidence from randomized controlled trials (RCTs) was used to estimate the effect of dapagliflozin, a new agent with a novel mechanism of action (SGLT-2 inhibition), relative to other anti-diabetes therapies after 1 year of treatment. METHODS A systematic literature review and Bayesian network meta-analysis (NMA) of RCTs involving anti-diabetes treatments added to metformin were...

DPP-4 inhibitors-renoprotection in diabetic nephropathy?

There is no doubt that rates of chronic kidney disease are escalating and that this rise is the main contributor to the increasing prevalence of diabetic nephropathy. It is also clear that the increase in kidney failure continues despite tight blood glucose and blood pressure control, as well as renin-angiotensin system blockade. In response, research into novel therapies to treat diabetic neph...

DPP 4 (dipeptidylpeptidase-4) inhibitors: beyond glycemic control

Type 2 diabetes is characterized by impaired insulin release from β-cell of pancreas and insulin resistance. Different classes of hypoglycemic drugs are available with different mechanism of action with nearly equipotent efficacy. GLP-1(glucagon like peptide-1) analogue and DPP 4 inhibitors are new developed molecules for the management of diabetes. They act via glucose dependent insulin releas...